COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

• Status: Completed
• Trial end date: 2019-08-13

Summary

To evaluate the effect of itraconazole or rifampin on the absorption, distribution, metabolism and elimination of COPANLISIB (BAY80-6946).

To evaluate the effect of copanlisib on QT/QTc intervals and left ventricular ejection fraction as parameters of cardiovascular safety.

• Phase: Phase 1

Details

• Lead Sponsor: Bayer
• Treatments: Hydroxyitraconazole; Itraconazole; Rifampin